Fr. 65.00

Evaluation of Outcome in Thymectomized Myasthenia Gravis Patient

English · Paperback / Softback

Shipping usually within 2 to 3 weeks (title will be printed to order)

Description

Read more

Myasthenia gravis is an autoimmune disease characterized by a fluctuating weakness of voluntary muscles (Busch et al. 1996). The weakness of myasthenic patients is due to an antibody-mediated autoimmune attack against acetylcholine receptor at neuromuscular junction (Urschel et al. 1998). Normally impulses travel down the nerve and nerve endings release a substance called acetylcholine. Acetylcholine binds or attaches to receptor on the muscle and makes the muscle contract. The strength of the contraction depends on how much acetylcholine the muscles receive. In myasthenia gravis, Immune system produces antibodies that block or destroy many of the receptor sites for acetylcholine in muscle. Because there are fewer receptor sites, the muscles get fewer nerve signals and become weak. In another form of MG, Immune system produces antibodies to the muscle specific tyrosine kinase protein.

About the author










Dr Mohammad Ata Ullah from a reputed muslim family of Noakhali, Bangladesh. Working at now BSMMU, Dhaka. Interested in research.

Product details

Authors Mohamma Ata Ullah, Mohammad Ata Ullah, Asi Baran Adhikary, Asit Baran Adhikary, Md Hoque, Md Rezwanul Hoque
Publisher LAP Lambert Academic Publishing
 
Languages English
Product format Paperback / Softback
Released 11.07.2018
 
EAN 9786139851249
ISBN 9786139851249
No. of pages 108
Dimensions 150 mm x 220 mm x 6 mm
Weight 180 g
Subject Natural sciences, medicine, IT, technology > Medicine > Medical professions

Customer reviews

No reviews have been written for this item yet. Write the first review and be helpful to other users when they decide on a purchase.

Write a review

Thumbs up or thumbs down? Write your own review.

For messages to CeDe.ch please use the contact form.

The input fields marked * are obligatory

By submitting this form you agree to our data privacy statement.